nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxymorphone—CYP3A4—prostate cancer	0.228	1	CbGaD
Oxymorphone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0691	0.154	CbGbCtD
Oxymorphone—CYP2D6—Bicalutamide—prostate cancer	0.0571	0.128	CbGbCtD
Oxymorphone—CYP2D6—Abiraterone—prostate cancer	0.0473	0.106	CbGbCtD
Oxymorphone—CYP3A4—Bicalutamide—prostate cancer	0.0363	0.0811	CbGbCtD
Oxymorphone—CYP3A4—Estramustine—prostate cancer	0.0338	0.0754	CbGbCtD
Oxymorphone—CYP3A4—Abiraterone—prostate cancer	0.0301	0.0672	CbGbCtD
Oxymorphone—CYP3A4—Flutamide—prostate cancer	0.0301	0.0672	CbGbCtD
Oxymorphone—CYP3A4—Cabazitaxel—prostate cancer	0.0223	0.0497	CbGbCtD
Oxymorphone—CYP3A4—Estrone—prostate cancer	0.0218	0.0486	CbGbCtD
Oxymorphone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0194	0.0433	CbGbCtD
Oxymorphone—CYP3A4—Conjugated Estrogens—prostate cancer	0.0142	0.0318	CbGbCtD
Oxymorphone—CYP3A4—Mitoxantrone—prostate cancer	0.0129	0.0289	CbGbCtD
Oxymorphone—CYP3A4—Estradiol—prostate cancer	0.0125	0.0279	CbGbCtD
Oxymorphone—CYP3A4—Prednisone—prostate cancer	0.0107	0.024	CbGbCtD
Oxymorphone—CYP2D6—Doxorubicin—prostate cancer	0.00875	0.0196	CbGbCtD
Oxymorphone—CYP3A4—Etoposide—prostate cancer	0.00816	0.0182	CbGbCtD
Oxymorphone—CYP3A4—Docetaxel—prostate cancer	0.00746	0.0167	CbGbCtD
Oxymorphone—CYP3A4—Doxorubicin—prostate cancer	0.00556	0.0124	CbGbCtD
Oxymorphone—Morphine—UGT2B15—prostate cancer	0.00136	0.237	CrCbGaD
Oxymorphone—Naloxone—TLR4—prostate cancer	0.00106	0.185	CrCbGaD
Oxymorphone—Buprenorphine—CYP2C18—prostate cancer	0.000534	0.0934	CrCbGaD
Oxymorphone—Oxycodone—CYP3A5—prostate cancer	0.000382	0.0668	CrCbGaD
Oxymorphone—Buprenorphine—CYP3A5—prostate cancer	0.000352	0.0615	CrCbGaD
Oxymorphone—Buprenorphine—CYP2A6—prostate cancer	0.00034	0.0595	CrCbGaD
Oxymorphone—Naloxone—ESR1—prostate cancer	0.000296	0.0518	CrCbGaD
Oxymorphone—Buprenorphine—CYP2C19—prostate cancer	0.000239	0.0419	CrCbGaD
Oxymorphone—Dihydrocodeine—CYP3A4—prostate cancer	0.000236	0.0413	CrCbGaD
Oxymorphone—Hydrocodone—CYP3A4—prostate cancer	0.000181	0.0317	CrCbGaD
Oxymorphone—Oxycodone—CYP3A4—prostate cancer	0.000165	0.0289	CrCbGaD
Oxymorphone—Buprenorphine—CYP3A4—prostate cancer	0.000152	0.0266	CrCbGaD
Oxymorphone—Naloxone—CYP3A4—prostate cancer	0.000151	0.0264	CrCbGaD
Oxymorphone—Hydromorphone—CYP3A4—prostate cancer	0.00015	0.0262	CrCbGaD
Oxymorphone—Morphine—CYP3A4—prostate cancer	0.000128	0.0223	CrCbGaD
Oxymorphone—Fatigue—Etoposide—prostate cancer	0.000105	0.000457	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000105	0.000456	CcSEcCtD
Oxymorphone—Pain—Etoposide—prostate cancer	0.000104	0.000453	CcSEcCtD
Oxymorphone—Constipation—Etoposide—prostate cancer	0.000104	0.000453	CcSEcCtD
Oxymorphone—Dizziness—Estradiol—prostate cancer	0.000104	0.000452	CcSEcCtD
Oxymorphone—Hypertension—Capecitabine—prostate cancer	0.000104	0.000451	CcSEcCtD
Oxymorphone—Dry mouth—Docetaxel—prostate cancer	0.000103	0.000449	CcSEcCtD
Oxymorphone—Chest pain—Capecitabine—prostate cancer	0.000102	0.000445	CcSEcCtD
Oxymorphone—Confusional state—Docetaxel—prostate cancer	0.000102	0.000444	CcSEcCtD
Oxymorphone—Anxiety—Capecitabine—prostate cancer	0.000102	0.000443	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000101	0.000442	CcSEcCtD
Oxymorphone—Oedema—Docetaxel—prostate cancer	0.000101	0.00044	CcSEcCtD
Oxymorphone—Vision blurred—Prednisone—prostate cancer	0.000101	0.000439	CcSEcCtD
Oxymorphone—Weight decreased—Doxorubicin—prostate cancer	0.0001	0.000437	CcSEcCtD
Oxymorphone—Feeling abnormal—Etoposide—prostate cancer	0.0001	0.000437	CcSEcCtD
Oxymorphone—Diarrhoea—Mitoxantrone—prostate cancer	0.0001	0.000436	CcSEcCtD
Oxymorphone—Dry mouth—Capecitabine—prostate cancer	9.98e-05	0.000435	CcSEcCtD
Oxymorphone—Vomiting—Estradiol—prostate cancer	9.98e-05	0.000435	CcSEcCtD
Oxymorphone—Pneumonia—Doxorubicin—prostate cancer	9.95e-05	0.000433	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Etoposide—prostate cancer	9.94e-05	0.000433	CcSEcCtD
Oxymorphone—Shock—Docetaxel—prostate cancer	9.94e-05	0.000433	CcSEcCtD
Oxymorphone—Nervous system disorder—Docetaxel—prostate cancer	9.91e-05	0.000432	CcSEcCtD
Oxymorphone—Dermatitis—Estradiol—prostate cancer	9.88e-05	0.000431	CcSEcCtD
Oxymorphone—Confusional state—Capecitabine—prostate cancer	9.87e-05	0.00043	CcSEcCtD
Oxymorphone—Tachycardia—Docetaxel—prostate cancer	9.86e-05	0.00043	CcSEcCtD
Oxymorphone—Headache—Estradiol—prostate cancer	9.83e-05	0.000428	CcSEcCtD
Oxymorphone—Skin disorder—Docetaxel—prostate cancer	9.82e-05	0.000428	CcSEcCtD
Oxymorphone—Agitation—Prednisone—prostate cancer	9.81e-05	0.000428	CcSEcCtD
Oxymorphone—Oedema—Capecitabine—prostate cancer	9.79e-05	0.000426	CcSEcCtD
Oxymorphone—Bradycardia—Epirubicin—prostate cancer	9.77e-05	0.000426	CcSEcCtD
Oxymorphone—Urticaria—Etoposide—prostate cancer	9.66e-05	0.000421	CcSEcCtD
Oxymorphone—Anorexia—Docetaxel—prostate cancer	9.63e-05	0.00042	CcSEcCtD
Oxymorphone—Shock—Capecitabine—prostate cancer	9.63e-05	0.00042	CcSEcCtD
Oxymorphone—Abdominal pain—Etoposide—prostate cancer	9.61e-05	0.000419	CcSEcCtD
Oxymorphone—Body temperature increased—Etoposide—prostate cancer	9.61e-05	0.000419	CcSEcCtD
Oxymorphone—Nervous system disorder—Capecitabine—prostate cancer	9.6e-05	0.000418	CcSEcCtD
Oxymorphone—Vertigo—Prednisone—prostate cancer	9.6e-05	0.000418	CcSEcCtD
Oxymorphone—Syncope—Prednisone—prostate cancer	9.58e-05	0.000417	CcSEcCtD
Oxymorphone—Tachycardia—Capecitabine—prostate cancer	9.55e-05	0.000416	CcSEcCtD
Oxymorphone—Skin disorder—Capecitabine—prostate cancer	9.51e-05	0.000414	CcSEcCtD
Oxymorphone—Urinary tract disorder—Epirubicin—prostate cancer	9.48e-05	0.000413	CcSEcCtD
Oxymorphone—Hyperhidrosis—Capecitabine—prostate cancer	9.46e-05	0.000412	CcSEcCtD
Oxymorphone—Hypotension—Docetaxel—prostate cancer	9.44e-05	0.000412	CcSEcCtD
Oxymorphone—Urethral disorder—Epirubicin—prostate cancer	9.41e-05	0.00041	CcSEcCtD
Oxymorphone—Loss of consciousness—Prednisone—prostate cancer	9.39e-05	0.000409	CcSEcCtD
Oxymorphone—Anorexia—Capecitabine—prostate cancer	9.33e-05	0.000406	CcSEcCtD
Oxymorphone—Nausea—Estradiol—prostate cancer	9.32e-05	0.000406	CcSEcCtD
Oxymorphone—Vomiting—Mitoxantrone—prostate cancer	9.3e-05	0.000405	CcSEcCtD
Oxymorphone—Convulsion—Prednisone—prostate cancer	9.25e-05	0.000403	CcSEcCtD
Oxymorphone—Visual impairment—Epirubicin—prostate cancer	9.25e-05	0.000403	CcSEcCtD
Oxymorphone—Hypertension—Prednisone—prostate cancer	9.22e-05	0.000402	CcSEcCtD
Oxymorphone—Dermatitis—Mitoxantrone—prostate cancer	9.21e-05	0.000401	CcSEcCtD
Oxymorphone—Headache—Mitoxantrone—prostate cancer	9.16e-05	0.000399	CcSEcCtD
Oxymorphone—Hypotension—Capecitabine—prostate cancer	9.14e-05	0.000398	CcSEcCtD
Oxymorphone—Insomnia—Docetaxel—prostate cancer	9.14e-05	0.000398	CcSEcCtD
Oxymorphone—Anxiety—Prednisone—prostate cancer	9.06e-05	0.000395	CcSEcCtD
Oxymorphone—Bradycardia—Doxorubicin—prostate cancer	9.04e-05	0.000394	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.03e-05	0.000393	CcSEcCtD
Oxymorphone—Dyspnoea—Docetaxel—prostate cancer	9.01e-05	0.000393	CcSEcCtD
Oxymorphone—Somnolence—Docetaxel—prostate cancer	8.99e-05	0.000392	CcSEcCtD
Oxymorphone—Eye disorder—Epirubicin—prostate cancer	8.97e-05	0.000391	CcSEcCtD
Oxymorphone—Hypersensitivity—Etoposide—prostate cancer	8.96e-05	0.00039	CcSEcCtD
Oxymorphone—Flushing—Epirubicin—prostate cancer	8.91e-05	0.000388	CcSEcCtD
Oxymorphone—Cardiac disorder—Epirubicin—prostate cancer	8.91e-05	0.000388	CcSEcCtD
Oxymorphone—Dyspepsia—Docetaxel—prostate cancer	8.9e-05	0.000388	CcSEcCtD
Oxymorphone—Insomnia—Capecitabine—prostate cancer	8.85e-05	0.000386	CcSEcCtD
Oxymorphone—Decreased appetite—Docetaxel—prostate cancer	8.79e-05	0.000383	CcSEcCtD
Oxymorphone—Urinary tract disorder—Doxorubicin—prostate cancer	8.77e-05	0.000382	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Docetaxel—prostate cancer	8.73e-05	0.00038	CcSEcCtD
Oxymorphone—Asthenia—Etoposide—prostate cancer	8.73e-05	0.00038	CcSEcCtD
Oxymorphone—Dyspnoea—Capecitabine—prostate cancer	8.72e-05	0.00038	CcSEcCtD
Oxymorphone—Oedema—Prednisone—prostate cancer	8.72e-05	0.00038	CcSEcCtD
Oxymorphone—Fatigue—Docetaxel—prostate cancer	8.71e-05	0.00038	CcSEcCtD
Oxymorphone—Angiopathy—Epirubicin—prostate cancer	8.71e-05	0.000379	CcSEcCtD
Oxymorphone—Urethral disorder—Doxorubicin—prostate cancer	8.7e-05	0.000379	CcSEcCtD
Oxymorphone—Nausea—Mitoxantrone—prostate cancer	8.68e-05	0.000378	CcSEcCtD
Oxymorphone—Immune system disorder—Epirubicin—prostate cancer	8.67e-05	0.000378	CcSEcCtD
Oxymorphone—Mediastinal disorder—Epirubicin—prostate cancer	8.65e-05	0.000377	CcSEcCtD
Oxymorphone—Constipation—Docetaxel—prostate cancer	8.64e-05	0.000377	CcSEcCtD
Oxymorphone—Pain—Docetaxel—prostate cancer	8.64e-05	0.000377	CcSEcCtD
Oxymorphone—Dyspepsia—Capecitabine—prostate cancer	8.61e-05	0.000375	CcSEcCtD
Oxymorphone—Pruritus—Etoposide—prostate cancer	8.6e-05	0.000375	CcSEcCtD
Oxymorphone—Shock—Prednisone—prostate cancer	8.58e-05	0.000374	CcSEcCtD
Oxymorphone—Visual impairment—Doxorubicin—prostate cancer	8.56e-05	0.000373	CcSEcCtD
Oxymorphone—Nervous system disorder—Prednisone—prostate cancer	8.55e-05	0.000372	CcSEcCtD
Oxymorphone—Tachycardia—Prednisone—prostate cancer	8.51e-05	0.000371	CcSEcCtD
Oxymorphone—Decreased appetite—Capecitabine—prostate cancer	8.51e-05	0.000371	CcSEcCtD
Oxymorphone—Skin disorder—Prednisone—prostate cancer	8.47e-05	0.000369	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Capecitabine—prostate cancer	8.45e-05	0.000368	CcSEcCtD
Oxymorphone—Fatigue—Capecitabine—prostate cancer	8.44e-05	0.000368	CcSEcCtD
Oxymorphone—Hyperhidrosis—Prednisone—prostate cancer	8.43e-05	0.000367	CcSEcCtD
Oxymorphone—Mental disorder—Epirubicin—prostate cancer	8.41e-05	0.000366	CcSEcCtD
Oxymorphone—Pain—Capecitabine—prostate cancer	8.37e-05	0.000365	CcSEcCtD
Oxymorphone—Constipation—Capecitabine—prostate cancer	8.37e-05	0.000365	CcSEcCtD
Oxymorphone—Malnutrition—Epirubicin—prostate cancer	8.35e-05	0.000364	CcSEcCtD
Oxymorphone—Feeling abnormal—Docetaxel—prostate cancer	8.33e-05	0.000363	CcSEcCtD
Oxymorphone—Diarrhoea—Etoposide—prostate cancer	8.32e-05	0.000363	CcSEcCtD
Oxymorphone—Anorexia—Prednisone—prostate cancer	8.31e-05	0.000362	CcSEcCtD
Oxymorphone—Eye disorder—Doxorubicin—prostate cancer	8.3e-05	0.000362	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Docetaxel—prostate cancer	8.26e-05	0.00036	CcSEcCtD
Oxymorphone—Flushing—Doxorubicin—prostate cancer	8.24e-05	0.000359	CcSEcCtD
Oxymorphone—Cardiac disorder—Doxorubicin—prostate cancer	8.24e-05	0.000359	CcSEcCtD
Oxymorphone—Flatulence—Epirubicin—prostate cancer	8.23e-05	0.000359	CcSEcCtD
Oxymorphone—Tension—Epirubicin—prostate cancer	8.2e-05	0.000357	CcSEcCtD
Oxymorphone—Nervousness—Epirubicin—prostate cancer	8.11e-05	0.000354	CcSEcCtD
Oxymorphone—Feeling abnormal—Capecitabine—prostate cancer	8.06e-05	0.000351	CcSEcCtD
Oxymorphone—Angiopathy—Doxorubicin—prostate cancer	8.06e-05	0.000351	CcSEcCtD
Oxymorphone—Dizziness—Etoposide—prostate cancer	8.04e-05	0.00035	CcSEcCtD
Oxymorphone—Immune system disorder—Doxorubicin—prostate cancer	8.02e-05	0.000349	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Capecitabine—prostate cancer	8e-05	0.000349	CcSEcCtD
Oxymorphone—Mediastinal disorder—Doxorubicin—prostate cancer	8e-05	0.000349	CcSEcCtD
Oxymorphone—Body temperature increased—Docetaxel—prostate cancer	7.99e-05	0.000348	CcSEcCtD
Oxymorphone—Abdominal pain—Docetaxel—prostate cancer	7.99e-05	0.000348	CcSEcCtD
Oxymorphone—Insomnia—Prednisone—prostate cancer	7.88e-05	0.000344	CcSEcCtD
Oxymorphone—Vision blurred—Epirubicin—prostate cancer	7.87e-05	0.000343	CcSEcCtD
Oxymorphone—Mental disorder—Doxorubicin—prostate cancer	7.78e-05	0.000339	CcSEcCtD
Oxymorphone—Urticaria—Capecitabine—prostate cancer	7.77e-05	0.000339	CcSEcCtD
Oxymorphone—Abdominal pain—Capecitabine—prostate cancer	7.74e-05	0.000337	CcSEcCtD
Oxymorphone—Body temperature increased—Capecitabine—prostate cancer	7.74e-05	0.000337	CcSEcCtD
Oxymorphone—Vomiting—Etoposide—prostate cancer	7.73e-05	0.000337	CcSEcCtD
Oxymorphone—Malnutrition—Doxorubicin—prostate cancer	7.73e-05	0.000337	CcSEcCtD
Oxymorphone—Agitation—Epirubicin—prostate cancer	7.68e-05	0.000334	CcSEcCtD
Oxymorphone—Dyspepsia—Prednisone—prostate cancer	7.67e-05	0.000334	CcSEcCtD
Oxymorphone—Dermatitis—Etoposide—prostate cancer	7.66e-05	0.000334	CcSEcCtD
Oxymorphone—Headache—Etoposide—prostate cancer	7.62e-05	0.000332	CcSEcCtD
Oxymorphone—Flatulence—Doxorubicin—prostate cancer	7.62e-05	0.000332	CcSEcCtD
Oxymorphone—Tension—Doxorubicin—prostate cancer	7.58e-05	0.00033	CcSEcCtD
Oxymorphone—Decreased appetite—Prednisone—prostate cancer	7.58e-05	0.00033	CcSEcCtD
Oxymorphone—Fatigue—Prednisone—prostate cancer	7.51e-05	0.000327	CcSEcCtD
Oxymorphone—Nervousness—Doxorubicin—prostate cancer	7.51e-05	0.000327	CcSEcCtD
Oxymorphone—Vertigo—Epirubicin—prostate cancer	7.5e-05	0.000327	CcSEcCtD
Oxymorphone—Syncope—Epirubicin—prostate cancer	7.49e-05	0.000326	CcSEcCtD
Oxymorphone—Constipation—Prednisone—prostate cancer	7.45e-05	0.000325	CcSEcCtD
Oxymorphone—Hypersensitivity—Docetaxel—prostate cancer	7.45e-05	0.000324	CcSEcCtD
Oxymorphone—Palpitations—Epirubicin—prostate cancer	7.38e-05	0.000322	CcSEcCtD
Oxymorphone—Loss of consciousness—Epirubicin—prostate cancer	7.34e-05	0.00032	CcSEcCtD
Oxymorphone—Vision blurred—Doxorubicin—prostate cancer	7.28e-05	0.000317	CcSEcCtD
Oxymorphone—Asthenia—Docetaxel—prostate cancer	7.25e-05	0.000316	CcSEcCtD
Oxymorphone—Convulsion—Epirubicin—prostate cancer	7.24e-05	0.000315	CcSEcCtD
Oxymorphone—Nausea—Etoposide—prostate cancer	7.22e-05	0.000315	CcSEcCtD
Oxymorphone—Hypertension—Epirubicin—prostate cancer	7.21e-05	0.000314	CcSEcCtD
Oxymorphone—Hypersensitivity—Capecitabine—prostate cancer	7.21e-05	0.000314	CcSEcCtD
Oxymorphone—Feeling abnormal—Prednisone—prostate cancer	7.18e-05	0.000313	CcSEcCtD
Oxymorphone—Pruritus—Docetaxel—prostate cancer	7.15e-05	0.000312	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Prednisone—prostate cancer	7.13e-05	0.000311	CcSEcCtD
Oxymorphone—Chest pain—Epirubicin—prostate cancer	7.11e-05	0.00031	CcSEcCtD
Oxymorphone—Agitation—Doxorubicin—prostate cancer	7.1e-05	0.000309	CcSEcCtD
Oxymorphone—Anxiety—Epirubicin—prostate cancer	7.09e-05	0.000309	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.06e-05	0.000308	CcSEcCtD
Oxymorphone—Asthenia—Capecitabine—prostate cancer	7.02e-05	0.000306	CcSEcCtD
Oxymorphone—Dry mouth—Epirubicin—prostate cancer	6.95e-05	0.000303	CcSEcCtD
Oxymorphone—Vertigo—Doxorubicin—prostate cancer	6.94e-05	0.000303	CcSEcCtD
Oxymorphone—Syncope—Doxorubicin—prostate cancer	6.93e-05	0.000302	CcSEcCtD
Oxymorphone—Urticaria—Prednisone—prostate cancer	6.92e-05	0.000302	CcSEcCtD
Oxymorphone—Pruritus—Capecitabine—prostate cancer	6.92e-05	0.000302	CcSEcCtD
Oxymorphone—Diarrhoea—Docetaxel—prostate cancer	6.92e-05	0.000301	CcSEcCtD
Oxymorphone—Abdominal pain—Prednisone—prostate cancer	6.89e-05	0.0003	CcSEcCtD
Oxymorphone—Body temperature increased—Prednisone—prostate cancer	6.89e-05	0.0003	CcSEcCtD
Oxymorphone—Confusional state—Epirubicin—prostate cancer	6.87e-05	0.0003	CcSEcCtD
Oxymorphone—Palpitations—Doxorubicin—prostate cancer	6.83e-05	0.000298	CcSEcCtD
Oxymorphone—Oedema—Epirubicin—prostate cancer	6.82e-05	0.000297	CcSEcCtD
Oxymorphone—Loss of consciousness—Doxorubicin—prostate cancer	6.79e-05	0.000296	CcSEcCtD
Oxymorphone—Shock—Epirubicin—prostate cancer	6.71e-05	0.000292	CcSEcCtD
Oxymorphone—Convulsion—Doxorubicin—prostate cancer	6.7e-05	0.000292	CcSEcCtD
Oxymorphone—Diarrhoea—Capecitabine—prostate cancer	6.7e-05	0.000292	CcSEcCtD
Oxymorphone—Nervous system disorder—Epirubicin—prostate cancer	6.69e-05	0.000291	CcSEcCtD
Oxymorphone—Dizziness—Docetaxel—prostate cancer	6.68e-05	0.000291	CcSEcCtD
Oxymorphone—Hypertension—Doxorubicin—prostate cancer	6.67e-05	0.000291	CcSEcCtD
Oxymorphone—Tachycardia—Epirubicin—prostate cancer	6.65e-05	0.00029	CcSEcCtD
Oxymorphone—Skin disorder—Epirubicin—prostate cancer	6.62e-05	0.000289	CcSEcCtD
Oxymorphone—Hyperhidrosis—Epirubicin—prostate cancer	6.59e-05	0.000287	CcSEcCtD
Oxymorphone—Chest pain—Doxorubicin—prostate cancer	6.58e-05	0.000287	CcSEcCtD
Oxymorphone—Anxiety—Doxorubicin—prostate cancer	6.56e-05	0.000286	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.53e-05	0.000285	CcSEcCtD
Oxymorphone—Anorexia—Epirubicin—prostate cancer	6.5e-05	0.000283	CcSEcCtD
Oxymorphone—Dizziness—Capecitabine—prostate cancer	6.47e-05	0.000282	CcSEcCtD
Oxymorphone—Dry mouth—Doxorubicin—prostate cancer	6.44e-05	0.00028	CcSEcCtD
Oxymorphone—Vomiting—Docetaxel—prostate cancer	6.43e-05	0.00028	CcSEcCtD
Oxymorphone—Hypersensitivity—Prednisone—prostate cancer	6.42e-05	0.00028	CcSEcCtD
Oxymorphone—Hypotension—Epirubicin—prostate cancer	6.37e-05	0.000278	CcSEcCtD
Oxymorphone—Dermatitis—Docetaxel—prostate cancer	6.37e-05	0.000277	CcSEcCtD
Oxymorphone—Confusional state—Doxorubicin—prostate cancer	6.36e-05	0.000277	CcSEcCtD
Oxymorphone—Headache—Docetaxel—prostate cancer	6.33e-05	0.000276	CcSEcCtD
Oxymorphone—Oedema—Doxorubicin—prostate cancer	6.31e-05	0.000275	CcSEcCtD
Oxymorphone—Asthenia—Prednisone—prostate cancer	6.25e-05	0.000273	CcSEcCtD
Oxymorphone—Vomiting—Capecitabine—prostate cancer	6.22e-05	0.000271	CcSEcCtD
Oxymorphone—Shock—Doxorubicin—prostate cancer	6.21e-05	0.00027	CcSEcCtD
Oxymorphone—Nervous system disorder—Doxorubicin—prostate cancer	6.19e-05	0.00027	CcSEcCtD
Oxymorphone—Pruritus—Prednisone—prostate cancer	6.17e-05	0.000269	CcSEcCtD
Oxymorphone—Insomnia—Epirubicin—prostate cancer	6.17e-05	0.000269	CcSEcCtD
Oxymorphone—Dermatitis—Capecitabine—prostate cancer	6.16e-05	0.000269	CcSEcCtD
Oxymorphone—Tachycardia—Doxorubicin—prostate cancer	6.16e-05	0.000268	CcSEcCtD
Oxymorphone—Headache—Capecitabine—prostate cancer	6.13e-05	0.000267	CcSEcCtD
Oxymorphone—Skin disorder—Doxorubicin—prostate cancer	6.13e-05	0.000267	CcSEcCtD
Oxymorphone—Hyperhidrosis—Doxorubicin—prostate cancer	6.1e-05	0.000266	CcSEcCtD
Oxymorphone—Dyspnoea—Epirubicin—prostate cancer	6.08e-05	0.000265	CcSEcCtD
Oxymorphone—Somnolence—Epirubicin—prostate cancer	6.06e-05	0.000264	CcSEcCtD
Oxymorphone—Anorexia—Doxorubicin—prostate cancer	6.01e-05	0.000262	CcSEcCtD
Oxymorphone—Nausea—Docetaxel—prostate cancer	6e-05	0.000262	CcSEcCtD
Oxymorphone—Dyspepsia—Epirubicin—prostate cancer	6e-05	0.000261	CcSEcCtD
Oxymorphone—Diarrhoea—Prednisone—prostate cancer	5.96e-05	0.00026	CcSEcCtD
Oxymorphone—Decreased appetite—Epirubicin—prostate cancer	5.93e-05	0.000258	CcSEcCtD
Oxymorphone—Hypotension—Doxorubicin—prostate cancer	5.89e-05	0.000257	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Epirubicin—prostate cancer	5.89e-05	0.000256	CcSEcCtD
Oxymorphone—Fatigue—Epirubicin—prostate cancer	5.88e-05	0.000256	CcSEcCtD
Oxymorphone—Pain—Epirubicin—prostate cancer	5.83e-05	0.000254	CcSEcCtD
Oxymorphone—Constipation—Epirubicin—prostate cancer	5.83e-05	0.000254	CcSEcCtD
Oxymorphone—Nausea—Capecitabine—prostate cancer	5.81e-05	0.000253	CcSEcCtD
Oxymorphone—Dizziness—Prednisone—prostate cancer	5.76e-05	0.000251	CcSEcCtD
Oxymorphone—Insomnia—Doxorubicin—prostate cancer	5.71e-05	0.000249	CcSEcCtD
Oxymorphone—Dyspnoea—Doxorubicin—prostate cancer	5.62e-05	0.000245	CcSEcCtD
Oxymorphone—Feeling abnormal—Epirubicin—prostate cancer	5.62e-05	0.000245	CcSEcCtD
Oxymorphone—Somnolence—Doxorubicin—prostate cancer	5.61e-05	0.000244	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Epirubicin—prostate cancer	5.57e-05	0.000243	CcSEcCtD
Oxymorphone—Dyspepsia—Doxorubicin—prostate cancer	5.55e-05	0.000242	CcSEcCtD
Oxymorphone—Vomiting—Prednisone—prostate cancer	5.54e-05	0.000241	CcSEcCtD
Oxymorphone—Dermatitis—Prednisone—prostate cancer	5.49e-05	0.000239	CcSEcCtD
Oxymorphone—Decreased appetite—Doxorubicin—prostate cancer	5.48e-05	0.000239	CcSEcCtD
Oxymorphone—Headache—Prednisone—prostate cancer	5.46e-05	0.000238	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.45e-05	0.000237	CcSEcCtD
Oxymorphone—Fatigue—Doxorubicin—prostate cancer	5.44e-05	0.000237	CcSEcCtD
Oxymorphone—Urticaria—Epirubicin—prostate cancer	5.42e-05	0.000236	CcSEcCtD
Oxymorphone—Constipation—Doxorubicin—prostate cancer	5.39e-05	0.000235	CcSEcCtD
Oxymorphone—Pain—Doxorubicin—prostate cancer	5.39e-05	0.000235	CcSEcCtD
Oxymorphone—Abdominal pain—Epirubicin—prostate cancer	5.39e-05	0.000235	CcSEcCtD
Oxymorphone—Body temperature increased—Epirubicin—prostate cancer	5.39e-05	0.000235	CcSEcCtD
Oxymorphone—Feeling abnormal—Doxorubicin—prostate cancer	5.2e-05	0.000226	CcSEcCtD
Oxymorphone—Nausea—Prednisone—prostate cancer	5.18e-05	0.000226	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Doxorubicin—prostate cancer	5.16e-05	0.000225	CcSEcCtD
Oxymorphone—Hypersensitivity—Epirubicin—prostate cancer	5.02e-05	0.000219	CcSEcCtD
Oxymorphone—Urticaria—Doxorubicin—prostate cancer	5.01e-05	0.000218	CcSEcCtD
Oxymorphone—Abdominal pain—Doxorubicin—prostate cancer	4.99e-05	0.000217	CcSEcCtD
Oxymorphone—Body temperature increased—Doxorubicin—prostate cancer	4.99e-05	0.000217	CcSEcCtD
Oxymorphone—Asthenia—Epirubicin—prostate cancer	4.89e-05	0.000213	CcSEcCtD
Oxymorphone—Pruritus—Epirubicin—prostate cancer	4.82e-05	0.00021	CcSEcCtD
Oxymorphone—Diarrhoea—Epirubicin—prostate cancer	4.66e-05	0.000203	CcSEcCtD
Oxymorphone—Hypersensitivity—Doxorubicin—prostate cancer	4.65e-05	0.000203	CcSEcCtD
Oxymorphone—Asthenia—Doxorubicin—prostate cancer	4.53e-05	0.000197	CcSEcCtD
Oxymorphone—Dizziness—Epirubicin—prostate cancer	4.51e-05	0.000196	CcSEcCtD
Oxymorphone—Pruritus—Doxorubicin—prostate cancer	4.46e-05	0.000194	CcSEcCtD
Oxymorphone—Vomiting—Epirubicin—prostate cancer	4.33e-05	0.000189	CcSEcCtD
Oxymorphone—Diarrhoea—Doxorubicin—prostate cancer	4.32e-05	0.000188	CcSEcCtD
Oxymorphone—Dermatitis—Epirubicin—prostate cancer	4.29e-05	0.000187	CcSEcCtD
Oxymorphone—Headache—Epirubicin—prostate cancer	4.27e-05	0.000186	CcSEcCtD
Oxymorphone—Dizziness—Doxorubicin—prostate cancer	4.17e-05	0.000182	CcSEcCtD
Oxymorphone—Nausea—Epirubicin—prostate cancer	4.05e-05	0.000176	CcSEcCtD
Oxymorphone—Vomiting—Doxorubicin—prostate cancer	4.01e-05	0.000175	CcSEcCtD
Oxymorphone—Dermatitis—Doxorubicin—prostate cancer	3.97e-05	0.000173	CcSEcCtD
Oxymorphone—Headache—Doxorubicin—prostate cancer	3.95e-05	0.000172	CcSEcCtD
Oxymorphone—Nausea—Doxorubicin—prostate cancer	3.75e-05	0.000163	CcSEcCtD
Oxymorphone—OPRM1—Signaling Pathways—ERBB3—prostate cancer	1.03e-05	0.000116	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—FGFR2—prostate cancer	1.03e-05	0.000116	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—IGF1—prostate cancer	1.03e-05	0.000116	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—EGFR—prostate cancer	1.03e-05	0.000115	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—BAD—prostate cancer	1.02e-05	0.000115	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—NCOA3—prostate cancer	1.01e-05	0.000113	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—MAP2K1—prostate cancer	9.98e-06	0.000112	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PHGDH—prostate cancer	9.96e-06	0.000112	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—UMPS—prostate cancer	9.96e-06	0.000112	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—ARG2—prostate cancer	9.96e-06	0.000112	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—IL2—prostate cancer	9.95e-06	0.000112	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—TERT—prostate cancer	9.92e-06	0.000111	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—PIK3CD—prostate cancer	9.91e-06	0.000111	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—PIK3CG—prostate cancer	9.88e-06	0.000111	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—APC—prostate cancer	9.88e-06	0.000111	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—PIK3CA—prostate cancer	9.82e-06	0.00011	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—SERPINE1—prostate cancer	9.8e-06	0.00011	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—EGF—prostate cancer	9.77e-06	0.00011	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—IRS1—prostate cancer	9.77e-06	0.00011	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—LDHB—prostate cancer	9.77e-06	0.00011	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—KRAS—prostate cancer	9.7e-06	0.000109	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—HPGDS—prostate cancer	9.63e-06	0.000108	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP3A5—prostate cancer	9.59e-06	0.000108	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP2C19—prostate cancer	9.57e-06	0.000107	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—FGF2—prostate cancer	9.49e-06	0.000107	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—GSK3B—prostate cancer	9.49e-06	0.000106	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—HIF1A—prostate cancer	9.48e-06	0.000106	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—NOS3—prostate cancer	9.36e-06	0.000105	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—INS—prostate cancer	9.36e-06	0.000105	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—ACHE—prostate cancer	9.34e-06	0.000105	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—GSTT1—prostate cancer	9.34e-06	0.000105	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PDHA1—prostate cancer	9.26e-06	0.000104	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—TCN2—prostate cancer	9.26e-06	0.000104	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTA3—prostate cancer	9.26e-06	0.000104	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—UCP3—prostate cancer	9.26e-06	0.000104	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—LEP—prostate cancer	9.26e-06	0.000104	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP2A6—prostate cancer	9.23e-06	0.000104	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CAV1—prostate cancer	9.17e-06	0.000103	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CREBBP—prostate cancer	9.16e-06	0.000103	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—JAK2—prostate cancer	9.09e-06	0.000102	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—KDR—prostate cancer	9.07e-06	0.000102	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—IGF1—prostate cancer	9.05e-06	0.000102	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—EGFR—prostate cancer	9.01e-06	0.000101	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—AKR1C3—prostate cancer	8.98e-06	0.000101	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PRKACB—prostate cancer	8.93e-06	0.0001	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—PIK3CA—prostate cancer	8.91e-06	0.0001	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—MDM2—prostate cancer	8.88e-06	9.96e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP17A1—prostate cancer	8.84e-06	9.92e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—ESR1—prostate cancer	8.84e-06	9.92e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—HSD3B1—prostate cancer	8.83e-06	9.92e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—SLC22A3—prostate cancer	8.83e-06	9.92e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—ERBB2—prostate cancer	8.75e-06	9.82e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—MAP2K1—prostate cancer	8.75e-06	9.82e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—PIK3CD—prostate cancer	8.69e-06	9.75e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—PIK3CB—prostate cancer	8.64e-06	9.7e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—BAD—prostate cancer	8.63e-06	9.68e-05	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	8.61e-06	9.66e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	8.59e-06	9.65e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—KRAS—prostate cancer	8.51e-06	9.55e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTA4—prostate cancer	8.47e-06	9.51e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—TBXAS1—prostate cancer	8.47e-06	9.51e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—NCOA2—prostate cancer	8.42e-06	9.45e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—APC—prostate cancer	8.35e-06	9.38e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	8.35e-06	9.38e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—FGF2—prostate cancer	8.32e-06	9.34e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CXCL8—prostate cancer	8.3e-06	9.32e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—IRS1—prostate cancer	8.26e-06	9.27e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—EGF—prostate cancer	8.26e-06	9.27e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTA2—prostate cancer	8.25e-06	9.26e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—NOS3—prostate cancer	8.21e-06	9.21e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.15e-06	9.15e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—ABCG5—prostate cancer	8.15e-06	9.15e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CDKN1B—prostate cancer	8.11e-06	9.1e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—SLC5A5—prostate cancer	8.04e-06	9.02e-05	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—AKT1—prostate cancer	8.02e-06	9e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—GSK3B—prostate cancer	8.02e-06	9e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—JAK2—prostate cancer	7.97e-06	8.95e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTA1—prostate cancer	7.96e-06	8.94e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CASP3—prostate cancer	7.94e-06	8.92e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—IL2—prostate cancer	7.93e-06	8.9e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—INS—prostate cancer	7.91e-06	8.88e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—IL6—prostate cancer	7.89e-06	8.86e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—NAT2—prostate cancer	7.87e-06	8.84e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—HSD3B2—prostate cancer	7.87e-06	8.84e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTO1—prostate cancer	7.87e-06	8.84e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP2E1—prostate cancer	7.85e-06	8.81e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	7.82e-06	8.77e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—MDM2—prostate cancer	7.78e-06	8.74e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—NQO1—prostate cancer	7.76e-06	8.71e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CREBBP—prostate cancer	7.75e-06	8.69e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCND1—prostate cancer	7.73e-06	8.68e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—ERBB2—prostate cancer	7.68e-06	8.61e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CTNNB1—prostate cancer	7.66e-06	8.6e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—IGF1—prostate cancer	7.65e-06	8.59e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—TH—prostate cancer	7.65e-06	8.58e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—EGFR—prostate cancer	7.61e-06	8.54e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	7.57e-06	8.5e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP3A4—prostate cancer	7.57e-06	8.49e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PLCB2—prostate cancer	7.55e-06	8.47e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—LRP2—prostate cancer	7.55e-06	8.47e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP2C18—prostate cancer	7.55e-06	8.47e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—MMP9—prostate cancer	7.51e-06	8.43e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CDKN1A—prostate cancer	7.48e-06	8.4e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—PTEN—prostate cancer	7.46e-06	8.38e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP1B1—prostate cancer	7.44e-06	8.35e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—P4HB—prostate cancer	7.4e-06	8.31e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	7.39e-06	8.3e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	7.34e-06	8.24e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—AKT1—prostate cancer	7.28e-06	8.17e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CXCL8—prostate cancer	7.28e-06	8.17e-05	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	7.27e-06	8.16e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	7.26e-06	8.15e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—GGT1—prostate cancer	7.21e-06	8.09e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.2e-06	8.08e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—KRAS—prostate cancer	7.19e-06	8.07e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—EP300—prostate cancer	7.12e-06	7.99e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	7.11e-06	7.98e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—NCOA1—prostate cancer	7.1e-06	7.97e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—FGF2—prostate cancer	7.03e-06	7.89e-05	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	7.03e-06	7.89e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.02e-06	7.88e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP19A1—prostate cancer	7e-06	7.85e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CASP3—prostate cancer	6.97e-06	7.82e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—IL2—prostate cancer	6.96e-06	7.81e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—NOS3—prostate cancer	6.93e-06	7.78e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—SRC—prostate cancer	6.92e-06	7.77e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—IL6—prostate cancer	6.92e-06	7.77e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—MED12—prostate cancer	6.9e-06	7.75e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GNG5—prostate cancer	6.85e-06	7.69e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCND1—prostate cancer	6.78e-06	7.61e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—RXRA—prostate cancer	6.75e-06	7.58e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—VEGFA—prostate cancer	6.74e-06	7.57e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—JAK2—prostate cancer	6.74e-06	7.57e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	6.72e-06	7.54e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—STAT3—prostate cancer	6.68e-06	7.49e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	6.61e-06	7.41e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—NCOA3—prostate cancer	6.6e-06	7.41e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—MMP9—prostate cancer	6.58e-06	7.39e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—MDM2—prostate cancer	6.58e-06	7.38e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	6.56e-06	7.36e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—PTEN—prostate cancer	6.54e-06	7.35e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—COMT—prostate cancer	6.5e-06	7.3e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—ERBB2—prostate cancer	6.49e-06	7.28e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—GSTP1—prostate cancer	6.47e-06	7.27e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	6.4e-06	7.18e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—AKT1—prostate cancer	6.39e-06	7.17e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—ITPR1—prostate cancer	6.37e-06	7.15e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—HPGDS—prostate cancer	6.29e-06	7.07e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.26e-06	7.02e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—EP300—prostate cancer	6.24e-06	7.01e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—MYC—prostate cancer	6.2e-06	6.96e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—TGFB1—prostate cancer	6.19e-06	6.95e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CXCL8—prostate cancer	6.15e-06	6.9e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTT1—prostate cancer	6.11e-06	6.85e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—ACHE—prostate cancer	6.11e-06	6.85e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—SRC—prostate cancer	6.07e-06	6.81e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—EGFR—prostate cancer	6.07e-06	6.81e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.03e-06	6.77e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—TYMS—prostate cancer	6.02e-06	6.75e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	6.01e-06	6.74e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—GSTM1—prostate cancer	5.95e-06	6.68e-05	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	5.94e-06	6.67e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—VEGFA—prostate cancer	5.91e-06	6.64e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CASP3—prostate cancer	5.89e-06	6.61e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—IL2—prostate cancer	5.88e-06	6.6e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.87e-06	6.59e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—STAT3—prostate cancer	5.85e-06	6.57e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—IL6—prostate cancer	5.85e-06	6.57e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PRKACB—prostate cancer	5.84e-06	6.55e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—LPL—prostate cancer	5.84e-06	6.55e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.78e-06	6.49e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—KRAS—prostate cancer	5.73e-06	6.43e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCND1—prostate cancer	5.73e-06	6.43e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	5.68e-06	6.37e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CYP1A1—prostate cancer	5.64e-06	6.33e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—ERCC2—prostate cancer	5.59e-06	6.28e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—MMP9—prostate cancer	5.56e-06	6.25e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	5.54e-06	6.22e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—PTEN—prostate cancer	5.53e-06	6.21e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—NCOA2—prostate cancer	5.51e-06	6.18e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—MYC—prostate cancer	5.44e-06	6.1e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—TGFB1—prostate cancer	5.43e-06	6.09e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—AKT1—prostate cancer	5.4e-06	6.06e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—EGFR—prostate cancer	5.32e-06	5.97e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—EP300—prostate cancer	5.28e-06	5.92e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	5.27e-06	5.91e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—MTHFR—prostate cancer	5.26e-06	5.9e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.25e-06	5.9e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PPARA—prostate cancer	5.16e-06	5.79e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.13e-06	5.76e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—SRC—prostate cancer	5.13e-06	5.76e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—TP53—prostate cancer	5.09e-06	5.72e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—NQO1—prostate cancer	5.07e-06	5.7e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—KRAS—prostate cancer	5.03e-06	5.64e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—TH—prostate cancer	5e-06	5.61e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—VEGFA—prostate cancer	5e-06	5.61e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—STAT3—prostate cancer	4.95e-06	5.55e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.86e-06	5.46e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CAV1—prostate cancer	4.85e-06	5.44e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GGT1—prostate cancer	4.71e-06	5.29e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—IL6—prostate cancer	4.66e-06	5.23e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—NCOA1—prostate cancer	4.64e-06	5.21e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	4.62e-06	5.18e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—MYC—prostate cancer	4.6e-06	5.16e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—TGFB1—prostate cancer	4.59e-06	5.15e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.57e-06	5.13e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—EGFR—prostate cancer	4.5e-06	5.05e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—TP53—prostate cancer	4.47e-06	5.01e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.42e-06	4.96e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—RXRA—prostate cancer	4.41e-06	4.95e-05	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—AKT1—prostate cancer	4.3e-06	4.83e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—COMT—prostate cancer	4.25e-06	4.77e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—KRAS—prostate cancer	4.25e-06	4.77e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTP1—prostate cancer	4.23e-06	4.75e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—INS—prostate cancer	4.18e-06	4.69e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—ITPR1—prostate cancer	4.16e-06	4.67e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—CREBBP—prostate cancer	4.09e-06	4.6e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—IL6—prostate cancer	4.09e-06	4.59e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—TYMS—prostate cancer	3.93e-06	4.42e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	3.9e-06	4.38e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—GSTM1—prostate cancer	3.89e-06	4.36e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.88e-06	4.36e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—LPL—prostate cancer	3.82e-06	4.28e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—TP53—prostate cancer	3.78e-06	4.24e-05	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—AKT1—prostate cancer	3.77e-06	4.23e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.69e-06	4.14e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—NOS3—prostate cancer	3.67e-06	4.12e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—ERCC2—prostate cancer	3.66e-06	4.1e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—IL6—prostate cancer	3.46e-06	3.88e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—MTHFR—prostate cancer	3.44e-06	3.86e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.38e-06	3.8e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PPARA—prostate cancer	3.37e-06	3.78e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PTGS2—prostate cancer	3.35e-06	3.76e-05	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—AKT1—prostate cancer	3.19e-06	3.58e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CAV1—prostate cancer	3.17e-06	3.56e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PTEN—prostate cancer	2.92e-06	3.28e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.89e-06	3.24e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—EP300—prostate cancer	2.79e-06	3.13e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—INS—prostate cancer	2.73e-06	3.07e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—CREBBP—prostate cancer	2.68e-06	3.01e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.54e-06	2.85e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—NOS3—prostate cancer	2.4e-06	2.69e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.21e-06	2.48e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PTGS2—prostate cancer	2.19e-06	2.46e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.06e-06	2.32e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PTEN—prostate cancer	1.91e-06	2.15e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—EP300—prostate cancer	1.82e-06	2.05e-05	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—AKT1—prostate cancer	1.69e-06	1.89e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.35e-06	1.51e-05	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—AKT1—prostate cancer	1.1e-06	1.24e-05	CbGpPWpGaD
